Celgene has presented data for three Phase II studies evaluating combination therapy with Revlimid and Rituximab in patients with indolent non-hodgkin's lymphoma during the 51st American Society of Hematology's annual meeting in New Orleans, LA.
Celgene presents data for three Phase II studies of Revlimid